Life Sciences Archive » March, 2014

Life Sciences - March, 2014

315 articles

• Eli Lilly Blocks Teva From Selling Generic Alimta
• Fed. Circ.'s Claim Construction Rule At Stake In Teva Case
• Justices Leave FCA Pleading Dispute To Circuits, For Now
• Fed. Circ. Snubs Patent Appeal Over Allergan Pinkeye Drug
• How Changes To 'Dear Doctor Letters' Will Impact Industry
• J&J Accepts $4B Carlyle Offer For Blood-Testing Unit
• Insurer Hits CVS With False Scripts Whistleblower Suit
• Fed. Circ. Says Generics Deals Exclude Endo's New Patents
• Patterson Belknap Can't Dump Surgical Stapling IP Suit
• Female Powerbrokers Q&A: Brownstein's Ellen Schulhofer
• Female Powerbrokers Q&A: Roetzel's Lori Heyer-Bednar
• High Court Agrees To Hear Teva MS Drug Patent Suit
• Warner Chilcott Bone Drug Patents Invalid, Judge Rules
• Sterigenics, PE Parent Spend $727M To Take Over Nordion
• Mass. Bans Painkiller Zohydro Until Abuse Is Addressed
• Hospira To Pay $60M To Settle Shareholder Class Action
• 6th Circ. Affirms Dismissal Of BioMimetic Shareholder Row
• Calif. Bill For Statewide Drug Disposal Program Advances
• GMO Food Fight: The Latest From The States And Feds
• FTC Eyes $1B Pay-For-Delay Win, Official Quips
• Pa. Appeals Court Won't Reconsider Asbestos Suits' Transfer
• Apotex Says It Doesn't Need To Re-Prove Cephalon Deceit
• Fed. Circ. Nixes Shire Win In Generic Lialda Case
• J&J Can't Avoid Class Action Over Aveeno 'Natural' Claims
• FDA Chief Questioned Over Staff Meeting With Trial Lawyers
• Female Powerbrokers Q&A: McDermott's Effie Silva
• Female Powerbrokers Q&A: Pillsbury's Susan Serota
• Condo Roccia Adds Ex-Kessler Topaz Patent Litigation Atty
• As E-Discovery Goes Global, Japan And South Korea Catch Up
• NY High Court Lets Biotronik Pursue Recall-Related Damages
• Novartis, Others To Curb Antibiotic Use In Livestock
• ITC Won't Invalidate Patent In Sleep-Aid Device Probe
• FDA Rips Med Device Co.'s Failure To Report Injuries
• Jury Charge Botched In Fen-Phen Fraud Case, 3rd Circ. Told
• Is The Misappropriation Theory Of Insider Trading Dead?
• Vitamin Shoppe Hit With Class Suit Over Enzyme Claims
• Legal Needs To Rethink Its Dropbox Account
• GSK Warns Of Tampering With Weight Loss Drug
• Female Powerbrokers Q&A: Gruber Hurst's Shonn Brown
• Female Powerbrokers Q&A: FordHarrison's Tiffany Downs
• High Court Changed Hatch-Waxman Cases — Nobody Noticed
• How Law Firms Can Stay Profitable While Clients Cut Costs
• Life Sciences Should Brace For Fla. Rad Source Ruling
• Schiff Nutrition Pays $5M In Dietary Supplement Labeling Row
• Pfizer Fails To Get Geodon Off-Label Use Case Tossed
• Merck Escapes Some Injury Claims In Fosamax MDL
• Vista Drops Suit Against Illumina Over $9B Roche Bid
• Merck $250M Sex Bias Suit Not Another Dukes, Plaintiffs Say
• 2 Firms Steal GC Hearts In Health, Pharma
• GSK Handed $106M Verdict For Paxil Generic Contract Breach
• Extra ACA Enrollment Time Boosts Health Care Industry
• J&J May Have Destroyed Vaginal Mesh Docs, DOJ Told
• Female Powerbrokers Q&A: Farella Braun's Mary McCutcheon
• Female Powerbrokers Q&A: Drinker Biddle's Jill Bronson
• Foley & Lardner Adds Ex-Nelson Mullins Health Atty In Fla.
• PhRMA Slams FTC's Rationale For Targeting Drugmakers
• Inyx CEO Sues Berger Over Liens For Unpaid Legal Fees
• Finnegan Trademark Pro Heads To Pierce Atwood
• Uncertain Future For Products Containing Mercury
• Justice Kennedy Holds Strings In ACA Contraception Case
• Leveling The Playing Field For Small Business
• FDA Lays Out Pediatric Study Requirements For Device Makers
• And Now A Word From The Panel: Snow Day!
• Immunomedics, UC End Spat Over Antibody Product IP
• Deals Rumor Mill: Merck, BlackBerry, Jun He
• Stryker, Alliant Pay $1M To Settle Qui Tam Suit Over VA Sales
• The Prolific Pragmatist: Judge Richard Posner
• Punitive Damages In Play In Pa. Risperdal Cases, Court Hears
• Female Powerbrokers Q&A: Labaton's Martis Alex
• Female Powerbrokers Q&A: Dinsmore's Joanne Schreiner
• FDA Cites Another Indian Drugmaker For Suspect Records
• Justices Mull Limits Of Religious Protection In ACA Case
• Watson Gets $17.8M Jolt For Medicaid Drug Pricing
• Little-Used Doctrine Bars Brain Life's IP Claims: Fed Circ.
• Colo. Justices Give Attys Way To Advise On Marijuana Law
• EU Scientists Begin Vaginal Mesh Safety Investigation
• Teva's Planned Generic Infringes Mylan Patents, Judge Says
• High Court Stays Mum On Teva MS Drug Patent Suit
• High Court Won't Hear Miss. Medical Equipment Tax Row
• Attys Size Up High Court's Stance On Contraception Case
• Testim Suits Bubble Up Against Auxilium in Pa.
• Bayer Can't Get Tolling Ruling Nixed In $100M Sex Bias Suit
• Md. High Court Slaps WL Gore With $29M Tax Bill
• Feds Say Ex-SAC Trader's Acquittal Bid Distorts Facts
• Perrigo Sues FDA For Failing To Publish Approval Of Gel
• Herbalife To Give Icahn 3 More Board Seats
• FDA Details Label Development For Fast-Tracked Drugs
• Female Powerbrokers Q&A: Perkins Coie's Susan Foster
• Female Powerbrokers Q&A: Gibson Dunn's Helgi Walker
• District Courts Grapple With High Court's Actavis Ruling
• Technology — Not Just For The Privileged Anymore
• 4 Elite New York Law Firms Keep Partner Ranks Lean
• NY, Chicago Home To Most Law360 400 Firms
• Jones Day Lands Top Spot In Law360 400
• In BigLaw, The Big Keep Getting Bigger
• Law360 Reveals 400 Largest US Law Firms
• J&J Ruling Removes FDA Warnings From Plaintiff Playbook
• Saline Shortage Demands Faster Fix, Hospitals Tell FDA
• ITC Launches Probe Of Dentsply Lithium Silicate Imports
• Medical Device Recalls Doubled Over Past Decade, FDA Says
• Novartis Defeats Ore. Aredia, Zometa Jaw Injury Suit
• UK's Mobile Medical Apps Guidance Parallels FDA's
• Pfizer Beats FCA Suit Over Pain Patch Marketing
• Deals Rumor Mill: Temasek, Danone, Air Berlin
• Texas Atty Wards Off $10M Fen-Phen Overbilling Judgment
• 9 High Court Questions To Watch For In Contraception Case
• Female Powerbrokers Q&A: Munger Tolles' Kristin Myles
• Female Powerbrokers Q&A: Glaser Weil's Patty Glaser
• Teva Bashes Buyers' Expert In Bid To Uphold Antitrust Win
• Avoid Inducement Liability With Early Opinion Of Counsel
• How To Reduce Risk, Make More Money In Contingency Cases
• Akin Gump Snags Ex-McDermott Patent Pro In Calif.
• Ex-Employee Calls For Sanctions In Fresenius FCA Suit
• Judge Blows Smoke On LA Pot Shops' Equal Protection Suit
• Proskauer Nabs Antitrust Pro For DC Office
• Sanofi Sues Alkem Over Generic Heart Medication
• KV Pharma Reaches $12.8M Deal To Settle Shareholder Action
• Wal-Mart, Others Dispensed Expired Meds, FCA Suit Says
• Actavis, Noven Reach Deal Over Generic ADHD Patch Plans
• Ark. High Court Overturns J&J's $1.2B Risperdal Fine
• Mayroy Sells 7% Stake In French Pharma Co. Ipsen
• Health Cos. Want Pa. Hospital's Antitrust Suit Dismissed
• Female Powerbrokers Q&A: Day Pitney's Beth Sher
• Female Powerbrokers Q&A: Thompson Hine's Kathie Brandt
• Medicaid Enforcement: 10 Areas To Watch
• Hawaii AG Sues Plavix Makers For Deceptive Marketing
• Whistleblower's Cephalon FCA Suit Headed To Pa. Court
• Geron Faces Investor Suit After FDA Halts Clinical Trial
• Sens. Seek More Clarity On FDA's Mobile Medical App Stance
• Stereotaxis Ducks Investor Suit Over Product Projections
• Volcano Doesn't Owe $27M On Artery Device, Judge Hears
• Deals Rumor Mill: Michael Foods, Carlyle, Blackstone
• Former Stago Director Says He Was Fired For Whistleblowing
• Alcon Can't Escape Oversize Drug Bottle Class Action
• Horizon Inks $660M Deal For Specialty Drugmaker
• Female Powerbrokers Q&A: Dentons' Jana Cohen Barbe
• Female Powerbrokers Q&A: Lindquist's Nancy Vollertsen
• The Merry Crusader: Judge Jed Rakoff
• Celgene Ducks Teva Unit's Breast-Cancer Drug IP Claims
• Eli Lilly Slams Bid To Dredge Up Zyprexa Past In Actos Row
• Antitrust Group Backs Cipro Buyers In Pay-For-Delay Row
• St. Jude Topples Volcano In Guide Wire IP Feud
• Win For Barr In Glaucoma Drug IP Suit Upheld By Fed. Circ.
• Pfizer Files 2 Suits To Block Torrent's Generic Viagra
• Biolitec Hit With $75M Judgment In IP Indemnification Feud
• McDermott Nabs Finnegan Patent Ace To Bolster DC Office
• FDA Rips Compounders Making Unapproved J&J Drug
• Exxon, BMS, Others Settle With Feds Over NJ Superfund Site
• Female Powerbrokers Q&A: Wolf Greenfield's Helen Lockhart
• Female Powerbrokers Q&A: Labaton's Christine Azar
• FDA Hammers Columbia Doc's Clinical Trial Oversight
• High Court Deals Major Blow To Criminal Defendants
• GTCR Invests $300M Into New Life Sciences Acquisition Co.
• Cephalon Slaps Dr. Reddy's With Suit Over Leukemia Drug
• Dilemmas Remain For Colo. Attorneys After Amendment 64
• Savient Gets Nod For Ch. 11 Disclosure Statement
• Texas Appeals Court Nixes Attys' Fees In Employment Fight
• FDA Floats Guidance On Medical Devices For Rare Diseases
• NJ High Court To Mull Protections For Watchdog Workers
• Sanofi Hit With $20M Suit Over Osteoarthritis Cream
• CORRECTED: Patent Theft Trial Over McDermott Docs Settles
• FDA Updates Active Ingredient Guidance For New Drug Studies
• Wholesalers Ask 2nd Circ. To Toss Shire Pay-For-Delay Win
• Female Powerbrokers Q&A: Greenberg Traurig's Lori Cohen
• Female Powerbrokers Q&A: Hangley's Ashely Chan
• Law Firms Of The Future Will Be The Lawyers Of The Past
• Sorry Fido, NJ Medicine Tax Breaks For Humans Only
• Think Before You Blog: 8 Considerations For Attorneys
• Forest Pays Up To $10M In MDL Over Celexa, Lexapro
• Lawmakers Want To Undo FDA's Approval Of New Painkiller
• Forest Labs Hit With Suit Over Antidepressant Marketing
• Comcast Doesn't Doom Avandia Insurer Class, Judge Told
• Ill. 'Innovator Liability' Case Is Setback For Drug Cos.
• Allen Matkins Aids $106M Buy Of South Lake Union Property
• NAD Refers Diet Supplement Maker's Ad Claims To FTC
• Herbalife Delays Annual Meeting To Continue Icahn Talks
• Female Powerbrokers Q&A: Frankfurt Kurnit's Victoria Cook
• Female Powerbrokers Q&A: Orrick's Denise Mingrone
• Allergan Exec Bonus Suit Should Be Axed, Judge Says
• NY AG's 'Antitrust Boutique' Shows No Signs Of Slowing
• Tough Corporate Tax Outlook Fueling 'Inversion' Deals
• Fed. Circ. Unimpressed By Stem Cell Patent Standing Claims
• Facebook Slap Shows FDA Has Eagle Eye On Social Media
• Boehringer Hit With New Sanctions In Pradaxa MDL
• FDA Chief Defends Hydrocodone Painkiller Approval
• BNLfood's Injunction Bid Revived In Baby Formula Row
• Landauer Gets Nod To Solicit Votes For Ch. 11 Plan
• Another Forest Investor Says $25B Actavis Offer Is Weak
• FDA Blackballs Sun Pharma Plant In Import Safety Crackdown
• Conn. Gov. Pushes $450M Tax Reform Package
• Calif. High Court Preserves $415M Verdict Against Actelion
• Safety Worries Prompt FDA Update On Injectables Dosing
• NJ Judge Higbee Promoted From Mass Torts To Appeals Court
• Female Powerbrokers Q&A: Foley's Mary Braza
• Female Powerbrokers Q&A: Alston Hunt's Louise Ing
• K&L Gates Lands Kilpatrick IP Pro For DC Office
• EV3 Asks Del. Court To Undo Appriva Investors' $250M Award
• Judge Invalidates Reissue Patent For Pfizer's Celebrex
• Pharmacies, AGs Claim Sides On FDA's Generic Label Plan
• Facebook Page Lands Drugmaker In Hot Water With FDA
• NJ, Fla. To Get Slices Of $22M Genzyme FCA Settlement
• FTC Gives Nod To $4.3B Dainippon-Edison Pharma Deal
• Whistleblower Urges High Court To Take Takeda FCA Case
• Fed. Circ. Denies Becton $1.9M Extra Fees In TheraSense Row
• Deals Rumor Mill: AT&T, KKR, Cars.com
• FTC To Investigate Herbalife Pyramid-Scheme Claims
• Activist Investor Says Herbalife Is Violating Chinese Law
• Female Powerbrokers Q&A: Katten's Shannon Broome
• Female Powerbrokers Q&A: Lindquist's Barbara Rummel
• Reed Smith Atty's Widow Gives Generic-Drug Plaintiffs Hope
• How They Won It: Kaye, Munger Ward Off Pay-For-Delay Case
• Baxter Asks High Court To Mull USPTO's Verdict-Nixing Power
• Medicare Part D Defeat Shows Perils Of Agency Overreach
• FTC Says It Can Place HSR Act Restrictions On Drug Cos.
• NJ Jury Orders Roche To Pay $1.5M For Accutane User's IBD
• Ending Physician Speaker Programs May Not Be A Good Thing
• IPR: A 2nd Bite At The Apple For Hatch-Waxman Litigants
• Fed. Circ. Says Medtronic Didn't Infringe Defibrillator Patents
• Teva Pays $27M To End Antipsychotic Drug Kickback Claims
• Female Powerbrokers Q&A: McCarter & English's Pastor
• Female Powerbrokers Q&A: Thompson Hine's Goldstein
• Myriad Loses Bid To Block Ambry Cancer Tests In Patent Row
• FDA Is Evolving On New Chemical Entity Exclusivity
• Teva Can't Dodge GSK's Wellbutrin False Ad Suit
• Fed. Circ. Affirms For Promega In DNA Analysis Patent Row
• Teva Prods High Court Amid Venue Fight In Painkiller Suit
• Feds Scrap Controversial Medicare Part D Changes
• Agilent Can't Get Rival's DNA Patent Ruled Invalid
• Sens. Want Probe Into Zohydro 'Pay To Play' Meetings
• J&J Unit To Pay $5.9M To End Mont. Risperdal Row
• Eli Lilly Beats Zyprexa Failure-To-Warn Suit In 8th Circ.
• GSK Spends $1B On Additional Stake In India Pharma Unit
• Female Powerbrokers Q&A: Nossaman's Yuliya Oryol
• Female Powerbrokers Q&A: Manatt's Linda Goldstein
• 10 Problems In The USPTO's New Training Memo
• Roche Defends Accutane Against New Evidence In NJ Retrial
• J&J Unit Hit With $3M Jury Verdict In Topamax Row
• Abbott, Shareholders Agree To Settle Depakote Marketing Suit
• Judge Mulls Revival Of Nexium Pay-For-Delay Row
• Deals Rumor Mill: Vivendi, Vodafone, InterMune
• 1000s Target Medicare Part D Changes
• Zyprexa Fines Irrelevant In Actos Trial, Eli Lilly Says
• DC Circ. Opens Door For Stem Cell Regulation By FDA
• Novartis Keeps Aredia, Zometa Suit In Calif. Federal Court
• China's Latest Merger Decision Reflects New Approach
• Female Powerbrokers Q&A: Edwards Wildman's Brown
• Female Powerbrokers Q&A: Greenberg Traurig's Mitchell
• PE-Backed Biomet Plans $100M IPO To Trim Debt
• How To Avoid Discovery Problems While Using The Cloud
• Justices Told Pom Juice Spat Shouldn't Affect Drug Labels
• Agilent Says Rival's DNA Patent Based On Law Of Nature
• AbbVie Pushes Fed. Circ. To Resurrect Antibody Patent Spat
• J&J Antibacterial Drug Risky For Pneumonia Patients: FDA
• Pharmacies Fear Tort Fallout From New Drug Labeling Rule
• $100M Deal In Meningitis Outbreak MDL Nears Finish Line
• Insurer Must Defend Distributor In W.Va. AG's Pill Mill Suit
• Daiichi Must Reveal Worker Contact Info In Sex Bias Suit
• Female Powerbrokers Q&A: Foley's Jill Nicholson
• Female Powerbrokers Q&A: Squire Sanders' Caroline Noblet
• Important Conflict Being Overlooked In Omnicare Case
• Roche, Novartis Fined $250M Over Drug Collusion In Italy
• USPTO May Reject Wide Range Of Patents Under New Rules
• Dems Side With FDA On Generic Drug Labeling Overhaul
• SC's Off-Label Marketing Suit Against Cephalon To Continue
• Ark. Generic Reglan Suit Tossed Following 8th Circ. Remand
• Schumer Wants HHS To Overrule FDA's Painkiller Approval
• More Contract Pharmacy Oversight For HHS 340B Program
• Forest Escapes Lexapro Marketing Class Action
• Eli Lilly, Boehringer Diabetes Drug Faces FDA Roadblock
• Novartis Sues Pharmaceuticals International Over Zometa IP
• 5 Takeaways From FDA's Off-Label Promotion Guidance
• Female Powerbrokers Q&A: Sedgwick's Anna Shimko
• Female Powerbrokers Q&A: Robins Kaplan's Tara Sutton
• Anonymous Blog Post Hurt Drug Co.'s Stock, Petition Says
• J&J Unit Fights Use Of New Topamax Label In Defect Suits
• Wiggin & Dana Boosts IP Practice With 4 New Partners
• The King Of Late Night: Judge Robert Gerber
• Venable Lures Consumer Products Atty From Arnold & Porter
• Endo Faces Multistate Inquiry Over Pelvic Mesh Products
• FDA Sticks To Guns In Final Guidance On Production Changes
• 8 Highlights From Obama's $77B HHS Budget Plan
• FDA Warns 3 Drug Compounders Over Sloppy Practices
• Tyco Can't Ditch Suit Over $60M Eli Lilly Warehouse Heist
• Lab That Froze Ted Williams' Head Fights Tell-All Book
• Generic Drug Cos. Push To Ax FTC Pay-For-Delay Suit
• J&J Unit's Topamax Warnings Were Inadequate, Jury Told
• FDA Custom Device Exemption Still Won't See Much Use
• GSK Can't Escape Suit Over Reed Smith Atty's Suicide
• Amarin Targets AstraZeneca In Suit Over Heart Medication
• HHS OIG Finds Inadequate Fraud Info Amid CMS Data Issues
• FCA Claimants Closely Watching For Direction On Rule 9(b)
• NJ Biotech Co. Can't Dodge Former CFO's Exit Package
• Tax Creativity Keeps Pot Industry Out Of IRS Hot Water
• Baker Botts Adds 2 Gov't Contracts Attys To DC Office
• Female Powerbrokers Q&A: Paul Hastings' Palmina Fava
• Female Powerbrokers Q&A: K&L Gates' Liz Thomas
• As Legal Profession Evolves, GCs Outpace The Norm
• Ex-DLA Piper Atty To Co-Lead Paul Hastings' Tech Deals Team
• Securities Defense Bar Has High Hopes Riding On Omnicare
• Pressure Mounts To Scrap Medicare Part D Changes
• Medtrica, Steris Prevail In Endoscopy Kit Patent Dispute
• High Court Won't Put DuPont On $18M Hook Over Enzyme IP
• Plaintiffs Accuse Lilly Of Perjury, Seek Actos Trial Win
• FDA Looks To Social Media To Monitor Product Hazards
• Health Plan Doesn't Need Cost Study For Drug Prices: Panel
• Nexium Buyers Urge Judge To Rethink Ranbaxy Win In MDL
• Texas Bar Fights Fraudster's High Court Disbarment Appeal
• Female Powerbrokers Q&A: Kaye Scholer's Rhonda Trotter
• Female Powerbrokers Q&A: Cooley's Barbara Borden
• Fat Loss Pill Maker Defeats Cert. Bid In False Ad Suit
• Another Court Rules FCA Isn't For Regulatory Violations
• Ear-Cleaning Product Marketer Accused Of False Advertising
• Deals Rumor Mill: Vivendi, J. Crew, Unilever
• Bogus 'Derived From Beet' Ads Duping Buyers, Suit Says
• High Court Agrees To Hear Omnicare Securities Case